HALOZYME THERAPEUTICS, INC.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$2.53B
↑+22.4% +$462Mvs FY2024
Total Liabilities
$2.48B
↑+45.7% +$777Mvs FY2024
Equity
$49M
↓-86.6% -$315Mvs FY2024
Cash
$134M
↑+15.5% +$18Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $2.53B | $2.06B |
| Current Assets | $825M | $1.09B |
| Cash | $134M | $116M |
| ST Investments | $0 | $0 |
| Receivables | $426M | $288M |
| Inventory | $176M | $142M |
| Other Current | $89M | $539M |
| Non-Current Assets | $1.70B | $978M |
| PPE | $44M | $41M |
| Goodwill | $580M | $417M |
| Intangibles | $981M | $402M |
| Investments | $0 | $0 |
| Other Non-Current | $94M | $119M |
| Total Liab+Eq | $2.53B | $2.06B |
| Current Liab. | $177M | $139M |
| Accounts Payable | $21M | $10M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $156M | $129M |
| Non-Current Liab. | $2.30B | $1.56B |
| Long-Term Debt | $2.14B | $1.51B |
| Other LT Liab. | $157M | $55M |
| Equity | $49M | $364M |
| Retained Earnings | $55M | $360M |
| Other Equity | $0 | $4M |
QuarterCharts · SEC EDGAR data · HALO · Comparing FY2025 vs FY2024